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Glutaric aciduria type 1 (GA1) is a rare autoso-
mal recessive disease caused by a deficiency of
glutaryl-coenzyme A dehydrogenase (GDH) (EC
1.3.99.7),1 which is an inborn error of lysine and
tryptophan metabolism, resulting in increased
formation and excretion of glutaric acid (GA), 
3-hydroxyglutaric acid (3-OH-GA), glutaconic
acid and glutarylcarnitine.2 Those metabolites
including GA, 3-OH-GA, and glutaconic acid
then accumulate in body fluids and tissues.3
Symptoms of GA1 are characterized by extrapyra-
midal movement disorders of varying degree,3
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Background/Purpose: Glutaric aciduria type 1 (GA1) is an inborn error of lysine and tryptophan metabolism.
There is a lack of initial diagnostic signs of the disease, but late treatment often results in severe neurologic
impairment. In this study, we analyzed the results of screening for GA1 in a Chinese population.
Methods: Dry blood spots were obtained at about 3 days of age from 357,307 newborns and tested for 
elevation of glutaryl (C5DC)-carnitine by tandem mass spectroscopy. A second sample of blood spots was
required from those cases with abnormal elevation of C5DC-carnitine (higher than the cut-off value) 
(recall). If the results remained abnormal, those cases were referred for confirmation of the diagnosis and
treatment.
Results: Between August 2001 and February 2005, there were 40 cases with C5DC-carnitine more than
0.13 µM (the cut-off value), from whom a second sample of blood spots was obtained (recall rate, 0.02%);
two cases were confirmed to be affected by GA1. Because of the low positive prediction rate using this cut-off
value, we elevated the cut-off value slightly. Between February 2005 and August 2006, there were eight
cases with C5DC-carnitine more than 0.22 µM from whom a second sample of blood spots was obtained
(recall rate, 0.01%); three cases were confirmed to be affected by GA1. All five cases with persistent elevation
of C5DC-carnitine were referred and diagnosis was confirmed in each, giving an incidence of 1 in 71,461
newborns. There were no false negatives. Magnetic resonance imaging studies obtained from four cases
showed frontotemporal atrophy at the time of diagnosis. Two cases were followed for over 1 year, and
under treatment with dietary control and carnitine supplementation, both had normal development and
neither exhibited a frank episode of encephalopathic crisis.
Conclusion: With properly established cut-offs, GA1 can be successfully screened for in populations with
a low incidence of the disease. Early treatment is likely to improve the outcome of cases discovered by
screening. [J Formos Med Assoc 2008;107(2):139–144]
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and develop in the majority of GA1 patients either
following an acute encephalopathy or, less fre-
quently, during an insidious disease course. Most
individuals who have experienced an encephalo-
pathic crisis are severely dystonic and markedly
disabled.3,4
GA1 is prevalent in some ethnic groups, and
screening and early treatment in these populations
have been shown to decrease the incidence of
striatal degeneration and possibly prevent neu-
rologic complications.5 In a review of 77 cases,
Strauss et al demonstrated that screening of
asymptomatic newborns with GA1 followed by
thoughtful prospective care reduced the incidence
of radiologically and clinically evident basal gan-
glia injury from approximately 90% to 35%.4 In
addition, the uninjured children had better de-
velopmental outcomes. However, in another study
that used mutation-based screening, some infants
treated before symptom onset were neurologically
affected.6 With advances in tandem mass spec-
trometry (MS/MS), routine neonatal screening
for GA1 by measuring glutaryl (C5DC)-carnitine
levels has been increasingly performed.7
Nevertheless, there are examples of false-negative
results from screening,8 and unsolved questions
about the screening and treatment of this disease
persist.9,10
In this study, we describe the results of screen-
ing for GA1 in 357,307 newborns in a Chinese
population.
Methods
During the period from August 2001 to August
2006, a total of 357,307 newborns, or two-fifths
of the annual births in Taiwan, were screened at
the National Taiwan University Hospital screening
center. MS/MS analysis of the acylcarnitines as
butyrated esters was performed on an API 2000™
LC/MS/MS System (Applied Biosystems—Sciex)
as previous described.11,12 A total of 6000 new-
borns were included in the establishment of the
cut-off value, which was derived from the popu-
lation mean plus 4 standard deviations initially,
for a C5DC-carnitine value of 0.13 µM. However,
it was later (February 2005) adjusted to the pop-
ulation mean plus 4.5 standard deviations, to
0.22 µM, because of the low positive prediction
rate. A repeat blood spot sample was required for
any newborn that had an elevated level on the
first test. Newborns positive for the repeat screen
were referred to the hospital. Confirmation tests
included urine organic acid analysis, GDH gene
mutation analysis, and brain magnetic resonance
imaging (MRI). Genomic DNA was extracted
from peripheral blood leukocytes according to
standard protocols after obtaining informed
consent from the parents. Twelve genomic frag-
ments covering the entire coding sequence and
the exon–intron borders of the GDH gene
(NC_000019, GI:42406306) were amplified by
polymerase chain reaction, and then subjected
to direct sequencing. The cDNA sequence
(NM_000159; GI: 50959149) was numbered
from the translation initiation site.
Once the diagnosis was confirmed, a diet
containing lysine-free/low-tryptophan formula
(XLYS, low TRY Analog; SHS International Ltd.,
UK) was started, and vitamins and carnitine
(50 mg/kg/day) were also given according to the
guidelines.3,13,14 We also gave an instruction sheet
to parents that described emergency treatment
during acute intercurrent illnesses.
Results
During the period under review, 48 cases with 
elevated C5DC-carnitine were identified and re-
quired second blood spots for retest; the recall
rate for the whole period was 0.01%. Prior to
February 2005, when the cut-off value for C5DC-
carnitine was 0.13 µM, there were 40 cases that
required a second blood spot test, and therefore
the recall rate was 0.02%. Amongst them, only two
cases were confirmed to be affected by GA1, and
the positive prediction rate was 5.0%. After the
cut-off value was adjusted to 0.22 µM in February
2005, eight cases required a second blood spot 
test and the recall rate decreased to 0.01%. 
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Three cases were confirmed and the positive pre-
diction rate increased to 37.5%. There was no
false-negative case. All the five confirmed cases
had elevated concentrations of GA and 3-OH-GA
in the urine. The positive prediction rate for the
confirmation process was therefore 100%, and
the incidence of GA1 in this Taiwanese population
was 1 in 71,461 newborns. No false-negative result
was observed during this study.
Four of the five cases were referred to our 
hospital for confirmation and treatment. The ini-
tial C5DC-carnitine levels at 3 days of age ranged
from 0.214 to 0.620 µM, and all cases presented
with macrocephaly at birth (Table). Initial brain
MRI performed at the age of 12–33 days revealed
frontotemporal atrophy in all four newborns
(Figure 1). Neurologic examination revealed no
obvious abnormality except for mild hypotonia
in Cases 1 and 2, who were the oldest out of the
four newborns (38 and 30 months, respectively)
and are described in more detail below. All cases
were treated immediately after diagnosis.
Case 1 had C5DC-carnitine levels of 0.620 µM
and 0.708 µM (cut-off, 0.13 µM) at the ages of 
3 and 14 days, respectively. Her birth weight 
was 2760 g (10–25th percentile), and her head
circumference was 33 cm (50th percentile); how-
ever, when we saw her at 18 days of age, her head
circumference was 36 cm (90th percentile), and
she was mildly hypotonic. Initial MRI revealed
bilateral frontotemporal atrophy (Figure 1A), but
follow-up at the age of 1 year showed no pro-
gression (Figure 2A). During her first year, there
was no encephalopathic crisis and her develop-
ment was normal except for mild hypotonia. Her
diet control was good, and plasma lysine and
tryptophan levels were around the lower limits
of normal ranges (Figure 3A). Unfortunately, she
sustained a head injury when she was 15 months
old. At her last visit, at about 3 years of age, her
mental development was good, but she was still
undergoing rehabilitation.
Case 2 had C5DC-carnitine levels of 0.214
and 0.319 µM (cut-off, 0.13 µM) at the ages of 
4 and 13 days, respectively. At 1 month of age,
her weight was 4076g (3–10th percentile), her head
circumference was 39 cm (> 90th percentile), and
she was mildly hypotonic. Initial MRI revealed
bilateral frontotemporal atrophy (Figure 1B).
However, MRI at 8 months of age showed mild
increase in signal intensity over the basal ganglia
(Figure 2B), and MRI at 28 months of age re-
vealed no further change (Figure 2D). Seizure-
like movement had been observed at the age of
10 months. She had GDH gene mutations
G178E and IVS 10-2 a > c. Dietary control was
good (Figure 3B). At her last visit, at 30 months
of age, she showed normal development.
Cases 3 and 4 were newly diagnosed patients.
Both patients showed mild macrocephaly, but
no hypotonia.
Discussion
GA1, first described in 1975,2 is quite common
in some ethnic groups, such as the Amish, but 
is thought to be very rare in most other popula-
tions.9 Most of the residents in Taiwan were orig-
inally from the Southeastern part of China, and
the actual incidence of GA1 in the Chinese Han
population is not clear. The GDH IVS 10-2 a > c
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Table. Clinical information from neonatal screening of patients positive for glutaric aciduria type 1 in Taiwan
Case
BBW BHG
GDH gene mutation
Glutaryl-carnitine (µM)
(percentile) (percentile) 1st DBS 2nd DBS 3rd DBS Cut-off
1 10–25th 50th IVS 10-2 A > C/IVS 10-2 A > C 0.62 0.708 0.886 < 0.13
2 10–25th 50th IVS 10-2 A > C/G178E 0.214 0.319 1.202 < 0.13
3 10–25th 75–90th G101E/R128X 0.596 0.604 0.364 < 0.22
4 50–75th 75–90th IVS 10-2 A > C/L410V 0.502 0.602 1.055 < 0.22
BBW = birth body weight; BHG = birth head girth; GDH = glutaryl-coenzyme A dehydrogenase; DBS = dry blood spot.
mutation appears to be common in Chinese. 
A study in Hong Kong reported a carrier frequency
of IVS 10-2 a > c of 1 in 120, and estimated the
incidence of affected patients with this particu-
lar genotype as 1 in 57,600.15 One report on
Taiwanese patients noted another common mu-
tation, G569A.16 The results from our study also
indicate that although the occurrence of GA1 is
rare, its incidence among residents of Taiwan 
appears to be high, and it is a very important 
inborn error in the population.
Macrocephaly and frontotemporal atrophy
were observed in all of our patients when they
were examined at about 1 month of age. These
symptoms have also been observed prenatally.5,17
Although early-onset frontotemporal atrophy was
generally thought not to be associated with long-
term prognosis, it does indicate the existence of
brain damage prior to symptom onset. In two of
our cases, this brain atrophy was not progressive.
It is possible that such patients have sufficient
brain reserve to allow for normal development 
if further damage by encephalopathic crisis does
not occur, and aggressive supportive care during
acute febrile episodes may be the most important
therapeutic regimen for preventing the occurrence
of basal ganglion damage.3,13 However, it may
also be the most difficult therapy to execute, as
demonstrated by the clinical course of cases 
described in the present study.
The appearance of subtle basal ganglia lesions
in Case 2 was unexpected, since she did not 
experience any frank encephalopathic crisis.
Nevertheless, dystonic attacks are frequently mis-
taken for epileptic seizures. It is possible that 
the infant experienced an incipient metabolic
crisis that caused the basal ganglion damage. The
clinical course of this patient also reflected the
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Figure 1. Initial brain magnetic resonance imaging of patients revealed bilateral frontotemporal atrophy and fluid collection
that was most evident in the middle cranial fossae: (A) Case 1; (B) Case 2; (C) Case 3; (D) Case 4.
difficulties and uncertainties in the treatment of
GA1. In our patients, we monitored plasma lysine
and tryptophan levels, which were kept low but
were adequate for normal growth of the children.
Strict dietary control risks essential amino acid
deficiency,18 decreases body tolerance to stress,
avoids catabolism,13 and possibly prevents tryp-
tophan deficiency that may lead to irritability
and sleep irregularity.19 Urinary GA and 3-OH-GA
excretion may not correlate well with disease
severity,20,21 and possibly may not be useful in
monitoring treatment.
In conclusion, neonatal screening for GA1 is
possible, with adequately low cut-off values.
Recall for a second blood spot test would delay
the initial diagnosis by up to 1 month, but this
Screening of glutaric aciduria type I
J Formos Med Assoc | 2008 • Vol 107 • No 2 143
A B
C D
8 m/o
28 m/o16 m/o
Figure 2. (A) Follow-up brain magnetic resonance imaging (MRI) of Case 1 at 1 year revealed no progression of the 
frontotemporal atrophy. Follow-up brain MRI of Case 2 at: (B) 8 months; (C) 16 months; and (D) 28 months revealed 
no progression of the frontotemporal atrophy, but abnormal signal intensity was observed over bilateral basal ganglia.
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Figure 3. Blood levels of lysine (Lys) and tryptophan (Trp) during diet control: (A) Case 1; (B) Case 2.
may not be a real concern. Treatment can be
started at an early stage, and while severe neuro-
logic complications cannot be prevented in all
patients, it is clear that outcome is better in 
patients who are treated early than in those who
present clinically. More studies, or different ther-
apeutic strategies, are necessary to ensure good
long-term prognosis.
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